31st Mar 2014 08:33
LONDON (Alliance News) - e-Therapeutics PLC Monday said it had achieved positive interim results from a UK study evaluating the safety, dosing and anti-tumour activity of its ETS2101 drug in patients with advanced solid cancer tumours.
In a statement, the company said that it had completed six dose escalation steps up to 22 mg/kg, and ETS2101 was found to be well tolerated at all doses by all patients with no serious adverse events reported. In an earlier cohort, a single incident of dose-limiting fatigue was noted, but that has not been repeated in any other patient to date, it said.
The company added that analysis of the trial data also indicates that tumour development might be being retarded by the activity of ETS2101 in patients who joined the trial with progressive disease with a wide variety of tumour types.
"The UK Clinical Investigators therefore intend to continue to enrol further patients at higher dose levels, and to continue to escalate until a maximum tolerated dose has been established. The observation that progression of the tumour might be affected by higher doses of ETS2101 is clearly one that the UK Principal Clinical Investigator is keen to explore further," the company said in a statement.
ETS2101 is a synthetic cannabinoid identified by e-Therapeutics? as a drug with potential in cancer treatment. Its preclinical studies provided evidence of activity in a wide variety of cancer cell lines. Two phase I studies of ETS2101 are ongoing, one in patients with primary or secondary brain cancers and one in patients with various advanced solid tumours.
e-Theapeutics shares were up 9.6% at 24.1 pence early Monday, one of the top gainers on AIM.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
ETX.L